Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled, Phase 1 Study of 2 Escalating, Single Subcutaneous Doses to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TTP4000 in Subjects With Alzheimer's Disease With Mild Cognitive Impairment
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
Age
50 - 85 years
Sex
ALL
Healthy Volunteers
No
Miami, Florida, United States
Durham, North Carolina, United States
High Point, North Carolina, United States
Start Date
October 1, 2011
Primary Completion Date
February 1, 2013
Completion Date
February 1, 2013
Last Updated
February 12, 2015
8
ACTUAL participants
TTP4000
DRUG
Placebo
DRUG
Lead Sponsor
vTv Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07033494